Clinical trials: Seizures
KCNT1-Related Epilepsy
A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy
The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive…
- Trial name
- K1Te (NCT04924153)
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Biogen
CDKL5 Deficiency Disorder
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old
This study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in…
- Trial name
- NCT05249556
- Testing
- Ganaxolone
- Volunteers
- 20 people
- Sponsor
- Immedica Pharma AB
Hearing Loss
Clinical Investigation and Validation of a Self-fitted Air-conduction Hearing Aid
Approximately 48 million people in the United States have hearing loss or hearing difficulties in noisy environments. Concha Inc.
- Trial name
- NCT06167161
- Testing
- Hearing aid
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Concha Inc.
Seizures
Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.
To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.
- Trial name
- NCT00141427
- Testing
- Pregabalin
- Where
- 57 sites in Belgium, Finland and 6 more
- Volunteers
- 540 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome
An Extended Access Program (EAP) for Perampanel
The main objective of this EAP is to ensure that participants participating in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401 continue to have access to perampanel until such time…
- Trial name
- NCT02307578
- Testing
- Perampanel
- Where
- 27 sites in Belgium, Chile and 8 more
- Sponsor
- Eisai Inc.
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.